You can buy or sell Inozyme Pharma and other stocks, options, and ETFs commission-free!
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA. The listed name for INZY is Inozyme Pharma, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 25, Pre-Market